Phase IIb Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Condition:   COVID-19 Interventions:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo Sponsors:   CanSino Biologics Inc.;   Beijing Institute of Biotechnology;   Jiangsu Province Centers for Disease Control and Prevention Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials